·         Dr. Lal PathLabs has launched India’s First Comprehensive Complement Testing Laboratory, offering several tests made available in the country for the very first time.

·         A 2024 study report suggested 30% increase in autoimmune disorders post-pandemic. People aged 31–45 years showed the sharpest rise.¹

·         Another report suggested nearly 70% of autoimmune patients in India are women, as highlighted at IRACON 2025. Hormonal and genetic factors contribute significantly.²

Bengaluru, 26 November, 2025: Dr. Lal PathLabs (DLPL), one of India’s leading diagnostic networks, today announced the launch of India’s first dedicated Complement Testing Laboratory, strengthening its position as India’s leading hub for autoimmune diagnostics. This advanced facility brings globally benchmarked complement assays to Indian patients, several for the first time in the country, helping doctors diagnose autoimmune, kidney, and recurrent infection related conditions faster, more accurately, and at earlier stages.

Why Complement Testing Matters Today

Autoimmune and inflammatory diseases are increasingly being recognized across India, with more patients seeking care for conditions that often begin with vague, overlapping symptoms. Many individuals experience fever, joint pain, swelling, fatigue, or kidney-related issues and may consult multiple doctors before receiving a clear diagnosis.

These delays occur because autoimmune diseases can progress silently, affecting vital organs long before symptoms become obvious. Complement testing helps uncover the underlying immune disturbance and provide clarity on why these symptoms occur and enabling earlier, more accurate diagnosis and treatment.

The complement system is a group of blood proteins that help fight infections, clear damaged cells, and protect vital organs. When this system is weak, the body, especially children, becomes prone to repeated or severe infections. When it becomes overactive, it can mistakenly attack healthy tissues, contributing to conditions such as lupus, certain kidney diseases like C3 glomerulopathy and atypical haemolytic uremic syndrome (HUS), vasculitis, rheumatoid arthritis, transplant rejection, and even sepsis.

Because the complement system can malfunction in different ways, understanding its activity is crucial. Complement testing measures important immune proteins such as C3, C4, and C5, helping identify whether the immune response is overactive, underactive, or malfunctioning, a vital step in diagnosing and managing autoimmune diseases early.

“Complement testing has long been underrepresented in India’s diagnostic landscape. By introducing functional and antibody-based complement assays such as C1q, C5, Factor B, Factor H antibody, AH50, and C1 INH functional, many for the first time in the country, we are enabling earlier and more precise insights into immune-mediated disease. This bridges the gap between research and routine clinical care.” Said Dr. Vandana Lal, Executive Director, Dr. Lal PathLabs.

“As a pioneer in specialized diagnostics, we are proud to offer India’s first comprehensive complement testing platform. This marks a major step toward faster diagnosis, better treatment decisions, and improved outcomes for millions living with autoimmune and kidney diseases” said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs.

The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards. For patients living with autoimmune or inflammatory conditions, the launch offers greater clarity and control over disease management. Early and precise diagnosis means better treatment outcomes, reduced healthcare costs, and improved quality of life.

The post Dr. Lal PathLabs Strengthens Autoimmune Diagnosis with India’s First Comprehensive Complement Lab appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

Amyloidosis is a disease where the abnormal or misfolded amyloid protein accumulates in various vital organs leading to loss of function or even death in some cases. More than 40 types of Amyloid proteins are discovered till date, and precise knowledge about the type of Amyloid helps doctors in choosing the correct treatment or management plan for the patient. Kidney, Heart, Lungs, Skin are the most common involved, however any organ in the body can be affected.

 Key Highlights: 

·         First-of-its-kind in South Asia – DLPL pioneers this advanced diagnostic solution.

·         Nationwide Availability – Samples can be collected from anywhere in India and sent to National Reference Lab, Rohini, New Delhi for testing.

·         Accurate Diagnosis – Helps doctors determine the specific type of Amyloid, enabling targeted treatment and better outcomes.

·         Access for Hospitals – All hospitals can facilitate sample collection for patients and send to Dr Lal PathLabs for testing.

Commenting on the launch, Mr. Shankha Banerjee, CEO of Dr. Lal PathLabs, said, “Our mission is to bring world-class diagnostics to India. By introducing this advanced Amyloidosis test, we aim to provide doctors with critical insights for accurate diagnosis and personalized treatment. We are proud to be the first diagnostic chain in South Asia to offer this cutting-edge solution.”

Adding further, Dr. Alok Sharma, R&D Head & Director Renal Pathology & Electron Microscopy, stated, “Accurate typing of Amyloid proteins is essential for guiding treatment decisions. This gold standard advanced test, powered by Laser Microdissection & Mass Spectrometry allows us to precisely identify amyloid subtypes, helping clinicians provide targeted care. With this launch, we are bringing global standards of Proteomics based diagnostics to patients across India.”

Dr. Lal PathLabs has launched this test, under the guidance of National Amyloidosis Centre, London (UK).

This innovation reaffirms Dr. Lal PathLabs’ commitment to delivering advanced, accessible, and reliable diagnostic services across India.

The post Dr. Lal PathLabs Becomes South Asia’s First Diagnostic Chain to Launch Advanced Test for Amyloidosis appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.